Targeting of bone-derived insulin-like growth factor-II by a human neutralizing antibody suppresses the growth of prostate cancer cells in a human bone environment.
Kimura T, Kuwata T, Ashimine S, Yamazaki M, Yamauchi C, Nagai K, Ikehara A, Feng Y, Dimitrov DS, Saito S, et al. Clin Cancer Res. 2010 Jan 1; 16(1):121-9. Epub 2009 Dec 22.